Cargando…

Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies

BACKGROUND: Concerns have been raised that treatment of COPD with inhaled corticosteroids may increase pneumonia risk. Responding to a request from the European Medicines Agency Pharmacovigilance Risk Assessment Committee, a pooled analysis of interventional studies compared pneumonia risk with inha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollis, Sally, Jorup, Carin, Lythgoe, Dan, Martensson, Gunnar, Regnell, Pontus, Eckerwall, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389656/ https://www.ncbi.nlm.nih.gov/pubmed/28435240 http://dx.doi.org/10.2147/COPD.S128358

Ejemplares similares

Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy
por: Ställberg, Björn, et al.
Publicado: (2015)

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
por: Kuna, P, et al.
Publicado: (2007)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016)

The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials
por: O’Byrne, Paul M., et al.
Publicado: (2017)

Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study
por: Kuna, Piotr, et al.
Publicado: (2013)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies
por: Lodise, Thomas P, et al.
Publicado: (2020)

Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis
por: Calabrese, Cecilia, et al.
Publicado: (2018)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Effect of bronchofiberscopic lavage with budesonide suspension on refractory mycoplasma pneumoniae pneumonia
por: Li, Ya, et al.
Publicado: (2022)

Budesonide Nebulization in the Treatment of Neonatal Ventilator Associated Pneumonia
por: Li, Baoqiang, et al.
Publicado: (2017)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies
por: Jorup, Carin, et al.
Publicado: (2014)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
por: Um, Soo Jung, et al.
Publicado: (2013)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
por: Hanania, Nicola A., et al.
Publicado: (2020)

Acetylcysteine and budesonide for the treatment of refractory Mycoplasma pneumoniae pneumonia in children: a clinical observation
por: Wang, Yanli, et al.
Publicado: (2023)

A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals
por: Song, Ivy H., et al.
Publicado: (2020)

Clinical efficacy of budesonide combined with acetylcysteine in the treatment of mycoplasma pneumonia infection
por: Chen, Jing, et al.
Publicado: (2023)

Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis
por: Mukkada, Vincent A., et al.
Publicado: (2023)

Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD
por: Ji, Jie, et al.
Publicado: (2016)

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019)

Effectivness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; a Randomized Clinical Trial
por: Aghili, Mehrad, et al.
Publicado: (2020)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Inhalable Nano-Dimpled Microspheres Containing Budesonide-PLGA for Improved Aerodynamic Performance
por: Han, Chang-Soo, et al.
Publicado: (2022)

Positioning As-needed Budesonide–Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2
por: Bateman, Eric D., et al.
Publicado: (2021)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
por: Trudo, Frank, et al.
Publicado: (2015)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
por: Wang, Cheng, et al.
Publicado: (2017)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
por: Jenkins, Christine R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pshdjp9ikhq06dh2qhk3o3t4cs